To read this content please select one of the options below:

The elderly, medicines and robust evidence from randomised control trials

Alan Earl‐Slater (Senior Lecturer in Health Economics, Department of Medicines Management, Keele University, Keele, Staffordshire, UK. Email: pya11@cc.keele.ac.uk)

Journal of Clinical Effectiveness

ISSN: 1361-5874

Article publication date: 1 March 1998

60

Abstract

This paper identifies and explores issues of medication, the elderly, and the problems in securing and using evidence from randomised control trials. Demographic and health care data are presented. While the elderly are a significant set of consumers of medicines, there is a lack of published evidence, in control trial format, on which medications are better for elderly patients. Even if all the trial evidence on a new drug was published before the drug was put on the market, as recently recommended, there are serious issues to consider in securing and using evidence from clinical trials. This paper indicates ten problems in securing and using evidence from randomised control trials. Three examples of randomised control trials involving the elderly are given. While it is easier to call for improvements in the evidence base than to achieve improvements, this paper argues that improvements are fundamentally necessary. This is because if no significant improvement comes through on the evidence base, we will never know if we are providing the elderly with the cost‐effective care and attention that they deserve.

Citation

Earl‐Slater, A. (1998), "The elderly, medicines and robust evidence from randomised control trials", Journal of Clinical Effectiveness, Vol. 3 No. 3, pp. 105-111. https://doi.org/10.1108/eb020883

Publisher

:

MCB UP Ltd

Copyright © 1998, MCB UP Limited

Related articles